Health Condition 1: L918- Other hypertrophic disorders of the skin
Conditions
Interventions
Intervention1: Intralesional injection of 5-fluorouracil: Keloid scars will receive intralesional 5-FU, 0.2 ml/sq cm (10 mg/sq cm) (50mg/ml ampoule) with a maximum dose of 100 mg in an adult. A 2 ml d
Sponsors
Lok Nayak Hospital and associated MAMC
Eligibility
Inclusion criteria
Inclusion criteria: All patients between 18-60 years, having keloid scars with maximum scar size of 20 cm2. If one patient has multiple scars, no more than two scar sites will be included in the study.
Exclusion criteria
Exclusion criteria: -Pregnancy and lactation -Patients with co-morbidities like diabetes, hypertension, coronary artery disease, chronic liver disease. -Any patient with history of treatment with intralesional steroid injection in previous six months for the same site. -Infected keloids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical scar assessment based on Vancouver Scar Scale (VSS) that scores the scars on four parameters namely pigmentation, vascularity, pliability and height.Timepoint: At the end of each injection session and till last follow up scheduled at monthly intervals for 2 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain assessment as per Visual Analogue Scale (VAS) Adverse effects such as ulceration, telengectasias, skin atrophy, infection, pigmentary changes, any other. Timepoint: At the end of each injection session and till last follow up scheduled at monthly intervals for 2 months. | — |
Countries
India
Contacts
Public ContactDr Vishwadeep
Lok Nayak Hospital
Outcome results
None listed